Headache News and Research

Latest Headache News and Research

New insights into devastating second impact syndrome

Physicians at Indiana University School of Medicine and the Northwest Radiology Network (Indianapolis, Indiana) report the case of a 17-year-old high school football player with second impact syndrome (SIS). A rare and devastating traumatic brain injury, SIS occurs when a person, most often a teenager, sustains a second head injury before recovery from an earlier head injury is complete.

2 Jan 2013

A screening tool to evaluate pre-menstrual disorders

Even though there are many women who do not notice any special symptoms, there are some whose pre-menstrual disorders hamper their everyday lives: depressive mood, anxiety, excessive emotional sensitivity, fatigue, lack of concentration, headache, etc.

21 Dec 2012

Alcohol and antibiotics: an interview with Dr Randall

Contrary to popular belief, there are only a handful of antibiotics that can interact with alcohol to cause unpleasant effects. The two main antibiotics you should definitely avoid drinking alcohol with are metronidazole (brand names include Flagyl) and tinidazole (brand names include Fasigyn).

18 Dec 2012

Global travel, climate warming could create right conditions for chikungunya outbreaks in the U.S.

Global travel and climate warming could be creating the right conditions for outbreaks of a new virus in this country, according to a new Cornell University computer model.

18 Dec 2012

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.

17 Dec 2012

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

Smoking ‘worsens hangovers’

People who smoke more than usual on the same day as drinking heavily are at increased risk for a hangover the following morning, with heavier smoking leading to a worse hangover, researchers say.

14 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Forest Laboratories, Inc. and Almirall, S.A. announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced updated survival results from the Phase III CLEOPATRA study, which showed that the combination of Perjeta (pertuzumab), Herceptin (trastuzumab) and docetaxel chemotherapy significantly extended the lives (overall survival) of people with previously untreated HER2-positive metastatic breast cancer (mBC), compared to Herceptin, chemotherapy and placebo.

10 Dec 2012

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

Sanofi Pasteur, the vaccines division of Sanofi, announced today that IMOJEV vaccine against Japanese encephalitis (JE) is now available in Australia.

10 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Smokers more likely to report hangover symptoms after heavy drinking

People who like to smoke when they drink may be at greater risk of suffering a hangover the next morning, according to a study in the January 2013 issue of the Journal of Studies on Alcohol and Drugs.

5 Dec 2012

Guineafowl may spread Crimean-Congo hemorrhagic fever virus

Turkey raises and releases thousands of non-native guineafowl to eat ticks that carry the deadly Crimean-Congo hemorrhagic fever virus. Yet research suggests guineafowl eat few ticks, but carry the parasites on their feathers, possibly spreading the disease they were meant to stop, says a Turkish biologist working at the University of Utah.

30 Nov 2012

Eisai announces FDA acceptance of AcipHex NDA for priority review

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for AcipHex Delayed-Release Sprinkle Capsules 5mg and 10mg for the proposed indication of healing of Gastroesophageal Reflux Disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children 1 to 11 years of age.

30 Nov 2012

Headache News and Research

Latest Headache News and Research

New insights into devastating second impact syndrome

A screening tool to evaluate pre-menstrual disorders

Alcohol and antibiotics: an interview with Dr Randall

Global travel, climate warming could create right conditions for chikungunya outbreaks in the U.S.

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

Iclusig gets FDA approval for two rare blood and bone marrow diseases

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Smoking ‘worsens hangovers’

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Janssen announces U.S. prescribing information update for EDURANT tablets

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

New survival results from Genentech’s Perjeta Phase III combination study on HER2-positive mBC

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Smokers more likely to report hangover symptoms after heavy drinking

Guineafowl may spread Crimean-Congo hemorrhagic fever virus

Eisai announces FDA acceptance of AcipHex NDA for priority review

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Headache News and Research

Latest Headache News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in